Clinical Trial Update: Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PDR001 in advanced or metastatic well-differentiated non-functional neuroendocrine tumors and poorly differentiated GEP-NEC; trial comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
• Well-differentiated Non-functional Neuroendocrine Tumor of Gastrointestinal Origin
• Well-differentiated Non-functional Neuroendocrine Tumor of Pancreatic Origin
• Well-differentiated Non-functional Neuroendocrine Tumor of Thoracic Origin

Drugs mentioned

• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Well-differentiated Non-functional NET of Thoracic Origin, Well-differentiated Non-functional NET of Gastrointestinal Origin | Phase 2 | Status: COMPLETED | Results posted: 2021-04-12